ArticleNature communications2019
B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 263 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
263 citing papers in PubMed, 366 citations in OpenAlex.
- Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial).Nature cancer · 2025Trial
- Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.Cancer cell · 2024Trial
- Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial.Nature communications · 2024Trial
- TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.Breast cancer research : BCR · 2024Trial
- Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study.Journal for immunotherapy of cancer · 2022Trial
- B cells and humoral immunity in melanoma: regulatory and autoimmune-like features and implications for immunotherapy.Oncoimmunology · 2026Review
- Prednisolone modulates CD8⁺ and regulatory T-cell activity to dampen response to immune checkpoint inhibitor therapy in melanoma.Oncoimmunology · 2026Article
- Tertiary lymphoid structures in gastrointestinal cancer: orchestrating tumour microenvironmental immune subcycles to elegantly amplify the cancer immunity cycle.Annals of medicine · 2026Review
- B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- The multifaceted roles of tumor-infiltrating plasma cells in cancer immunology.Fundamental research · 2026Review
- Humoral immunity in cancer.Signal transduction and targeted therapy · 2026Review
- Circulating B cell and T cell activation states predict clinical outcomes in melanoma and reveal dynamic immune reinvigoration with checkpoint inhibitor immunotherapy.Journal for immunotherapy of cancer · 2026Article
- Vitamin B5 supports anti-PD1 response in HER2-positive gastric cancer and enhances interaction between naïve B cells and T cells.Nature communications · 2026Article
- Multiplexed single-cell and spatial profiling reveal B cells and tertiary lymphoid structures as prognostic indicators in pleural mesothelioma.British journal of cancer · 2026Article
- Predicting Response to Immune Checkpoint Inhibitors in Melanoma: Emerging Approaches in Digital Pathology, Spatial Profiling and Machine Learning.International journal of molecular sciences · 2026Review
- A Multiresolution Breast Cancer CIBERSORTx Resource Validated for Accuracy, Interpretive Limits, and Biological and Clinical Coherence in Tumor Microenvironment Deconvolution.Methods and protocols · 2026Article
- Activating a B cell immune response regresses immunologically cold tumours.Nature nanotechnology · 2026Article
- Defining the rules of engagement: B cells, antibodies and cancer control.Cellular & molecular immunology · 2026Review
- Vaccine-expanded plasmablast-like B cells are associated with response to dendritic cell therapy in metastatic melanoma.Journal of experimental & clinical cancer research : CR · 2026Article
- Phenotypic, functional, prognostic and predictive significance of B-cell and antibody responses in human melanoma: a scoping review.The British journal of dermatology · 2026Article
203 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 7 institutions in 5 countries.
Funding
Abstract
Tumor associated inflammation predicts response to immune checkpoint blockade in human melanoma. Current theories on regulation of inflammation center on anti-tumor T cell responses. Here we show that tumor associated B cells are vital to melanoma associated inflammation. Human B cells express pro- and anti-inflammatory factors and differentiate into plasmablast-like cells when exposed to autologous melanoma secretomes in vitro. This plasmablast-like phenotype can be reconciled in human melanomas where plasmablast-like cells also express T cell-recruiting chemokines CCL3, CCL4, CCL5. Depletion of B cells in melanoma patients by anti-CD20 immunotherapy decreases tumor associated inflammation and CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.